ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition

1. Deal Value: ArriVent has acquired Alphamab for $615 million to expand its ADC (Antibody-Drug Conjugate) portfolio.
2. ADC Portfolio: The acquisition is a strategic move to bulk out ArriVent's ADC portfolio, enhancing its position in the biotech industry.
3. Biotech Industry: The deal highlights the ongoing consolidation and growth in the biotech sector, particularly in the ADC space.
4. Financing: The $615 million deal underscores the significant investments being made in biotechnology and the ADC market.